Sage Therapeutics to Present at the Neurocritical Care Society 14th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming poster presentations at the Neurocritical Care Society 14th Annual Meeting, taking place from September 15-18 in National Harbor, Md.

Below is the schedule for the poster presentations:

**Date:** Friday, September 16, 2016  
**Poster Presentation Time:** 5:30 p.m. - 6:30 p.m. EDT  
**Location:** Gaylord National Resort & Convention Center, Prince George Exhibit Hall A  
**Poster Number:** 10  
**Title:** Preclinical Pharmacology and Pharmacodynamic Interactions of SAGE-547: Relevance to Super-Refractory Status Epilepticus

**Date:** Friday, September 16, 2016  
**Poster Presentation Time:** 5:30 p.m. - 6:30 p.m. EDT  
**Location:** Gaylord National Resort & Convention Center, Prince George Exhibit Hall A  
**Poster Number:** 168  
**Title:** Pharmacokinetics of SAGE-547 in Patients with Super-Refractory Status Epilepticus

**Date:** Friday, September 16, 2016  
**Poster Presentation Time:** 5:30 p.m. - 6:30 p.m. EDT  
**Location:** Gaylord National Resort & Convention Center, Prince George Exhibit Hall A  
**Poster Number:** 172  
**Title:** SAGE-547 (allopregnanolone injection) for the Treatment of Super-Refractory Status Epilepticus: Response and Relationship to Underlying Patient Characteristics

**Date:** Friday, September 16, 2016  
**Poster Presentation Time:** 5:30 p.m. - 6:30 p.m. EDT  
**Location:** Gaylord National Resort & Convention Center, Prince George Exhibit Hall A  
**Poster Number:** 174  
**Title:** Phase 1/2 Open-Label Data Suggest that Heterogeneity of Presentation and High Burden of Comorbid Illness Do Not Impact the Activity of SAGE-547 in Patients with Super-Refractory Status Epilepticus

**Date:** Saturday, September 17, 2016
In addition, Sage will host a lunch symposium featuring key opinion leaders. Details are as follows:

**Poster Presentation**

**Time:** 5:30 p.m. - 6:30 p.m. EDT  
**Location:** Gaylord National Resort & Convention Center, Prince George Exhibit Hall A  
**Poster Number:** 165  
**Title:** Hemodynamic Properties of SAGE-547 in Patients with Super-Refractory Status Epilepticus: Results from a Phase 1/2 Clinical Trial

In addition, Sage will host a lunch symposium featuring key opinion leaders. Details are as follows:

**Date:** Saturday, September 17, 2016  
**Time:** 12:00 p.m. - 1:00 p.m. EDT  
**Location:** Gaylord National Resort & Convention Center, Maryland Ballroom C  
**Title:** Diagnosis and Management of Super-Refractory Status Epilepticus

**About Sage Therapeutics**

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and is being developed for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit [www.sagerx.com](http://www.sagerx.com).

View source version on [businesswire.com](http://www.businesswire.com/news/home/20160916005142/en/)

**Investors:** Sage Therapeutics  
Paul Cox, 617-299-8377  
paul.cox@sagerx.com

**Media:** Sage Communications LLC  
Maureen L. Suda, 585-387-9248  
maureen.suda@sagerx.com

**Source:** Sage Therapeutics

News Provided by Acquire Media